Illán Gómez Fátima, Alcaraz Tafalla M Soledad, Pascual Díaz Mercedes, Carrillo Alcaraz Andrés
Sección de Endocrinología y Nutrición, Hospital Universitario Morales Meseguer, Murcia, Spain.
Med Clin (Barc). 2004 Oct 23;123(14):535-7. doi: 10.1016/s0025-7753(04)74587-x.
Type 2 diabetes mellitus is associated with an augmented risk for cardiovascular disease. The levels of C-reactive protein (CRP), the prototypic marker of inflammation, are associated with an increased risk for cardiovascular events. The statins have direct anti-inflammatory effects. Thus, we tested the effects of atorvastatin on levels of CRP on patients with type 2 diabetes.
We evaluated CRP in baseline and 6 months after onset of 20 mg daily atorvastatin therapy of 30 patients with type 2 diabetes with hyperlipidemia. Clinical and biochemical data were obtained.
CRP-levels were significantly decreased after treatment with atorvastatin compared with baseline (median change: -4,99 mg/l; p < 0.001). We observed an correlation between CRP baseline with body mass index (r = 0.429; p = 0.018), serum fibrinogen (r = 0.607; p = 0.001) and microalbuminuria (r = 0.470; p = 0.01). Conversely, there was no significant correlation between CRP baseline with LDL cholesterol. The CRP reduction was significantly correlated with fasting glucose (r = -0.457; p = 0.019) and glycosylated hemoglobin at 6 months (r = -0.421; p = 0.03).
These results confirm findings from previous studies that atorvastatin reduce CRP levels in a largely LDL cholesterol independent manner.
2型糖尿病与心血管疾病风险增加相关。炎症的典型标志物C反应蛋白（CRP）水平与心血管事件风险增加有关。他汀类药物具有直接的抗炎作用。因此，我们测试了阿托伐他汀对2型糖尿病患者CRP水平的影响。
我们评估了30例伴有高脂血症的2型糖尿病患者在每日服用20mg阿托伐他汀治疗基线期及治疗6个月后的CRP水平。获取了临床和生化数据。
与基线相比，阿托伐他汀治疗后CRP水平显著降低（中位数变化：-4.99mg/l；p<0.001）。我们观察到CRP基线水平与体重指数（r=0.429；p=0.018）、血清纤维蛋白原（r=0.607；p=0.001）和微量白蛋白尿（r=0.470；p=0.01）之间存在相关性。相反，CRP基线水平与低密度脂蛋白胆固醇之间无显著相关性。CRP降低与空腹血糖（r=-0.457；p=0.019）和6个月时的糖化血红蛋白（r=-0.421；p=0.03）显著相关。
这些结果证实了先前研究的发现，即阿托伐他汀在很大程度上以不依赖低密度脂蛋白胆固醇的方式降低CRP水平。
